Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that ...

The American Federation for Aging Research (AFAR) and Hevolution Foundation are pleased to announce the third cohort of theHevolution/AFAR New ...

Zenith launched the Chronomaster Revival Daisuke Jigen Edition, its fourth Lupin The Third collaboration The 37mm microblasted titanium chronograph features a vintage-inspired beige dial Limited to ...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional ...

Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing SC451 Investigational New Drug Application (IND) as ...

(1) To reflect a non-cash charge to operating expense for selling, general, and administrative stock-based compensation. (2) To reflect a non-cash charge to operating expense for research and ...

LOS ANGELES, November 06, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025.

President Donald Trump has said it is “pretty clear” the US Constitution does not permit him to run for the third term in office, after days of speculation prompted by claims from allies there was a ...